Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Kidney Cancer Test Approved by CLIA, New York

NEW YORK (GenomeWeb News) – Cancer Genetics said today it has received CLIA and New York approval to offer its microarray-based kidney cancer test.

As a result, the Rutherford, NJ-based firm has launched the test, called UroGenRA-Kidney, as part of its Kidney Complete Program. The test is intended for kidney cancer diagnosis and subtyping in its own laboratory, said Cancer Genetics, which went public in early April.

The test provides genomic data for differentiating the three malignant renal cell carcinoma subtypes — clear cell, papillary, and chromophobe RCC — from oncocytoma, a benign form of renal cancer. The test also is to help clinicians determine appropriate treatment, depending on the cancer subtype.

According to Cancer Genetics, UroGenRA-Kidney may "improve diagnosis and prevent unnecessary and costly surgical procedures."

The test was developed to aid in diagnosing needle biopsy and resected specimens. In many cases, surgery is recommended after diagnosis, but for those patients who don't require surgery, the test will help in deciding on an appropriate therapy based on the tumor genomic profiling, the company added.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.